Last reviewed · How we verify

ropivacaine plus clonidine

University Hospital, Lille · FDA-approved active Small molecule

Ropivacaine blocks sodium channels to provide local anesthesia, while clonidine enhances analgesia by activating alpha-2 adrenergic receptors.

Ropivacaine blocks sodium channels to provide local anesthesia, while clonidine enhances analgesia by activating alpha-2 adrenergic receptors. Used for Regional anesthesia and analgesia (peripheral nerve blocks, epidural anesthesia).

At a glance

Generic nameropivacaine plus clonidine
SponsorUniversity Hospital, Lille
Drug classLocal anesthetic with adjuvant alpha-2 agonist
TargetVoltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing action potential generation and nerve conduction. Clonidine, an alpha-2 adrenergic agonist, potentiates the analgesic effect when combined with local anesthetics, likely through central and peripheral mechanisms including reduced catecholamine release and enhanced inhibitory neurotransmission. This combination is used to extend the duration and improve the quality of regional anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: